| Date Filed | Type | Description |
| 04/26/2023 |
20-F
| Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: |
| 03/27/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 03/22/2023 |
15-12G
| Form 15-12G - Securities registration termination [Section 12(g)]: |
| 03/21/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/21/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/21/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/21/2023 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/21/2023 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 03/21/2023 |
8-K
| Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits Interac... |
| 02/14/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 02/09/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 02/01/2023 |
SC 13G/A
| FEDERATED HERMES, INC. reports a 6.6% stake in CASI PHARMACEUTICALS, INC. |
| 01/31/2023 |
8-K
| Acquisition/merger/asset purchase announced |
| 11/14/2022 |
8-K
| Quarterly results |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 09/23/2022 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data|
Docs:
|
"CASI PHARMACEUTICALS ANNOUNCES EXIT OF JUVENTAS INVESTMENT TO STRENGTHEN BALANCE SHEET ROCKVILLE, MD. and BEIJING, China CASI Pharmaceuticals, Inc. , a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products , today announced that CASI Biopharmaceuticals Co., Ltd, a subsidiary of CASI Pharmaceuticals, Inc. , entered into an Equity Transfer Agreement with Shenzhen Jiadao Gongcheng Equity Investment Fund, LLP , pursuant to which CASI Wuxi agreed to transfer its equity interest in Juventas Biotechnology Co., Ltd. amounting to 12.0098% total Juventas equity to Jiadao Gongcheng for RMB 240.87 million . The Equity Transfer Agreement states there will be two even payment installments from Jiadao Gongcheng: one payment to be made..." |
|
| 08/12/2022 |
8-K
| Quarterly results|
Docs:
|
"CASI PHARMACEUTICALS ANNOUNCES SECOND QUARTER 2022 FINANCIAL RESULTS ROCKVILLE, MD. and BEIJING, China CASI Pharmaceuticals, Inc. , a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today reported financial results for the second quarter of 2022. Wei-Wu He, Ph.D., CASI’ s Chairman and Chief Executive Officer, commented, “We are pleased to report $8.6 million in EVOMELA ® sales revenue for the second quarter of 2022. This is an increase of 19% compared to the same period last year. Our sales and marketing team is proven to be resilient, rapidly adapting strategies to address COVID-19 related challenges to ensure that our priories remain on track.” Dr. He continued, “Equipped with experience from EVOMELA and the ab..." |
|
| 08/12/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 06/21/2022 |
SC 13D/A
| He Wei-Wu reports a 19% stake in CASI Pharmaceuticals, Inc. |
| 05/26/2022 |
8-K
| Quarterly results |
| 05/25/2022 |
8-K
| Quarterly results |
| 05/25/2022 |
8-K
| Quarterly results |
| 05/24/2022 |
8-K
| Quarterly results |
| 05/24/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
8-K
| Quarterly results |
| 05/12/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/02/2022 |
8-K
| Quarterly results |
| 04/15/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 04/04/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
| 03/28/2022 |
8-K
| Quarterly results |
| 03/28/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
| 03/04/2022 |
8-K
| Quarterly results |
| 02/16/2022 |
8-K
| Quarterly results |
| 02/14/2022 |
SC 13G/A
| Consonance Capital Management LP reports a 0% stake in CASI PHARMACEUTICALS INC |
|